Search Results - michael+goggins

7 Results

Sort By:

Diagnostics and Therapeutic Monitoring Using AI Analysis Integrated with Magnetic Resonance Spectral Patterns of Biofluids

Unmet needPancreatic ductal adenocarcinoma (PDAC) is the most frequent form of pancreatic cancer, with a survival rate of less than 10% at five years largely due to late-stage diagnosis1. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, which is the leading cause of cancer death worldwide, primarily due to metastatic disease2....

Published: 9/27/2024 | Inventor(s): Meiyappan Solaiyappan, Santosh Bharti, Zaver Bhujwalla, Michael Goggins, Malcolm Brock

Keywords(s):

Category(s): Technology Classifications > Diagnostics

Most Pancreatic Ductal Adenocarcinomas have Detectable Telomere Fusions and their Detection in Pancreatic Cyst Fluids Predicts the Grade of Dysplasia of Intraductal Papillary Mucinous Neoplasms

Unmet Need Physicians must determine whether patients with cystic tumors of the pancreas will be operated on or receive further imaging and monitoring. Biomarkers that can inform the physician of the state of progression of the tumor, as well as predict the neoplastic nature of the cyst, would be valuable for determining treatment course. Specifically,...

Published: 9/26/2024 | Inventor(s): Michael Goggins, Tatsuo Hata

Keywords(s): Assay, Cancers, Clinical Diagnostics, Disease Indication, In Vitro Diagnostics, Pancreatic Cancer

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Research Tools > Assays, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools, Clinical and Disease Specializations > Oncology > Pancreatic Cancer

PALB2 Gene Mutations Identify Susceptibility to DNA Damaging Agents

PALB2 Gene Mutations Identify Susceptibility to DNA Damaging AgentsJHU Ref #: C10869Unmet NeedPancreatic cancer is predicted to be the second leading cause of cancer-related death by 2030 (Siegel et al., 2020). However, many patients present with advanced disease, and typical broad-spectrum chemotherapeutic treatments are often insufficient. Precision...

Published: 9/26/2024 | Inventor(s): Ralph Hruban, Bert Vogelstein, Kenneth Kinzler, Victor Velculescu, Scott Kern, Sian Jones, Michael Goggins, Manuel Hidalgo, Alison Klein, James Eshleman, Donald Parsons

Keywords(s): Biomarker, Clinical Diagnostics, In Vitro Diagnostics, Risk Stratification

Category(s): Technology Classifications > Computers, Electronics & Software > Precision Medicine Tools, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Computers, Electronics & Software, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Technology Classifications > Diagnostics > Precision Medicine Tools

SPARC/osteonectin is a Frequent Target for Aberrant Methylation in Pancreatic Adenocarcinoma

C04245: SPARC/osteonectin is a Frequent Target for Aberrant Methylation in Pancreatic Adenocarcinoma Technical Details: Deregulated expression of SPARC/osteonectin, a secreted glycoprotein with multiple biological functions, has been associated with the progression of various cancers. Using microarrays, we previously identified SPARC as one of the...

Published: 9/26/2024 | Inventor(s): Norihiro Sato, Michael Goggins

Keywords(s): Adenocarcinoma, Biomarker, Cancers, Clinical Diagnostics, Diagnostic Biomarker, Disease Indication, In Vitro Diagnostics, Pancreatic Cancer, Pancreatic ductal adenocarcinoma, Pancreatic Ductal Adenocarcinoma

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Oncology > Adenocarcinoma, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Clinical and Disease Specializations > Oncology > Pancreatic Ductal Adenocarcinoma, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology

Discovery of Novel Targets for Aberrant Methylation in Pancreatic Carcinoma Using High-throughput Microarrays

C04187: Discovery of Novel Targets for Aberrant Methylation in Pancreatic Carcinoma Using High-throughput Microarrays Technical Details: In order to identify potential targets for aberrant methylation in pancreatic cancer, we analyzed global changes in gene expression profiles of 4 pancreatic cancer cell lines after treatment with the demethylating...

Published: 9/26/2024 | Inventor(s): Norihiro Sato, Michael Goggins

Keywords(s): Assay, Biomarker, Cancers, Clinical Diagnostics, Disease Indication, In Vitro Diagnostics, Pancreatic Cancer

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Technology Classifications > Research Tools > Assays, Technology Classifications > Diagnostics, Technology Classifications > Diagnostics > In Vitro Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools

Isolation of Pancreatic Fibroblasts Including Pancreatic Cancer Associated Fibroblasts and Immortalization of these into Cell Lines

C11855: Immortalized Normal Human Pancreatic and Pancreatic Cancer Associated FibroblastsNovelty: Immortalized fibroblast cell lines established from pancreatic cancer tissue and normal pancreatic tissue.Value Proposition: Cancer-associated stromal fibroblast cells (CAF) have been identified to be involved in pancreatic tumor growth. Therefore CAFs...

Published: 9/26/2024 | Inventor(s): Michael Goggins

Keywords(s): Basic Research Biomarker, Cancers, Cell Lines, Discovery/Research Tools, Disease Indication, Human Cell Lines, In Vitro Research Tool, Pancreatic Cancer

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Technology Classifications > Research Tools > Cell Lines, Technology Classifications > Research Tools > Human Cell Lines, Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools

Identification of DNA Sequences Differentially Methylated in Pancreatic Cancer

C03825: Identification of DNA Sequences Differentially Methylated in Pancreatic Cancer Technical Details: Researchers at Johns Hopkins University have used the techniques of methylated CpG island amplification (MCA) coupled with representational difference analysis (RDA) to isolate 42 clones, which were shown to be differentially methylated in a...

Published: 9/26/2024 | Inventor(s): Takashi Ueki, Michael Goggins

Keywords(s): Biomarker, Cancers, Clinical Diagnostics, Diagnostic Biomarker, Disease Indication, In Vitro Diagnostics, Pancreatic Cancer

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities